The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications

Author(s): Berkin O. Ulgen, Matthew G. Field, Waqas Qureshi, Richard A. Knight, Anastasis Stephanou, David S. Latchman, Diego Vasquez, Sean P. Barry, Louis II Saravolatz, Gabriele M. Scarabelli, Giuseppe Faggian, Alessandro Mazzucco, Louis Saravolatz, Carol-Chen-Scarabelli, Tiziano M. Scarabelli

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 6 , Issue 2 , 2011


Minocycline is a semi-synthetic tetracycline that inhibits bacterial protein synthesis and hence is used for the treatment of many infectious diseases. Over the years, many other interesting properties of minocycline have been identified and been used to make patents which include anti-inflammatory, anti-apoptotic, matrix metalloproteinase inhibitor and free oxygen radical scavenger activity. Ischemia-reperfusion injury is a concern for almost every clinical specialty and minocycline seems to be an attractive cytoprotective agent that can ameliorate the damage due to these properties. Ischemia-reperfusion injury is a complex process and involves various pathways that lead to cell death. This review focuses on the body of evidence describing various proposed mechanisms of action of minocycline and its current experimental use in various animal models of ischemia-reperfusion injury.

Keywords: Apoptosis, ischemia-reperfusion injury, minocycline, ISCHEMIA, Free Radical Scavenger, TETRACYCLINES, Anti-apoptosis, Matrix Metalloproteinases, Cardiovascular Apparatus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [123 - 132]
Pages: 10
DOI: 10.2174/157489011795933783
Price: $65

Article Metrics

PDF: 9